BURBANK, CA–(Marketwire – October 18, 2010) –  Imaging3™, Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, announced today that the company has completed the previously announced institutional transaction and has successfully been funded.

“We are pleased to announce the completion of this transaction, which was facilitated by Wharton Capital Partners, Ltd.,” stated Dean Janes, the company’s Chairman/CEO.

About Imaging3

Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company’s website at http://www.imaging3.com for more information

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, technological obsolescence, competition from other medical instrument(s) and imaging companies, lack of capital, unexpected costs, failure or delay of FDA approval, absence of revenue, the impact on the national and local economies resulting from an economic recession or terrorist actions, and U.S. actions subsequently; unavailability of financing for the Company or its customers, product malfunction and potential product liability claims, and other factors detailed in reports filed by the Company.

VICTORIA, BRITISH COLUMBIA–(Marketwire – Oct. 18, 2010) – Following today’s trading halt by Investment Industry Regulatory Organization of Canada, CardioComm Solutions, Inc. (TSX VENTURE:EKG) (the “Company”) today confirmed that there is no material information pertaining to the Company which has not been disclosed.

About CardioComm Solutions, Inc.

CardioComm Solutions, Inc. (“CardioComm”) has been a consistent provider of ECG management software solutions in the English speaking world for the past 21 years. Its products are marketed as Global ECG Management System (GEMS™) and GlobalCardio™. CardioComm is ISO 13485 certified and its products have been cleared for sale in the United States, Canada and the European Union. CardioComm’s competitive advantage is built upon 2 ECG patents, a unique FDA approved ECG analysis algorithm, a world class ECG (signal) viewer and a back-end ECG data management control system. CardioComm’s technology enables the recording, transfer, viewing, analyzing, reporting and storing of electrocardiograms (EKGs) over a global virtual healthcare network by physicians for the diagnosis and management of cardiac patients. CardioComm provides an ECG management solution which complements the majority of the world’s cardiac event monitors, including those intended for the home and tele-health market. CardioComm products are sold worldwide to hospitals, call centers and physicians offices through a combination of its external distribution network and its North American based sales team.

On behalf of the Board of Directors of CardioComm Solutions, Inc.

Anatoly Langer, Chairman of the Board

BLUE BELL, PA–(Marketwire – October 18, 2010) –  PDS, a leading developer of human resource, benefits, recruiting and payroll systems, today announced that its Vista HRMS^® solution has been selected by Tender Touch Rehab Services, Inc. Based in Lakewood, N.J., Tender Touch will utilize Vista HRMS to manage HR, Payroll, Benefits, Recruiting, Self-service and Workflow for all of its employees located at various facilities throughout New York, New Jersey, Pennsylvania and Delaware.

“Our existing solution could handle some of our HR requirements, but was very limited in the areas of employee benefits, payroll, recruitment and reporting,” explained Ellie Hertz, HR representative at Tender Touch. “We needed an all-in-one solution that is accessible by all of our authorized staff members. With Vista HRMS’ ease of use, quick search capabilities and streamlined reporting, it is the kind of solution we have been dreaming about. Vista HRMS is the total package and it will enable us to focus our energies on more strategic initiatives to better serve our employees.”

“The data available to us was limited and the processes required to obtain the information we needed were cumbersome, causing more errors,” explained Amitai Levin, director of HR for Tender Touch. “In addition to the increase in accuracy we expect from Vista, we also believe that it will automate many of our processes, like approvals, notifications and benefits enrollment, allowing us to be more productive and provide our customers — the employees of Tender Touch — the best service possible.”

Tender Touch will be going live on Vista HRMS in late 2010. 

About PDS
In the HRMS software development business for more than 35 years, PDS is a provider of a feature-rich, completely integrated human resource, benefits administration, recruiting and payroll software application that enables organizations to focus on more strategic issues and less on administrative HR, benefits and payroll activities. In addition to core HRMS functionality, Vista HRMS^® offers self-service, English-language query tool and workflow automation. PDS also provides a full range of professional services to a wide variety of industries in the U.S. and in Canada. Founded in 1974, PDS is a privately-held company headquartered in Blue Bell, Pa. For more information on PDS or PDS’ Vista HRMS solution and services visit www.pdssoftware.com.

PDS and the PDS logo are registered trademarks and Vista is a trademark of Personnel Data Systems Inc. All other trademarks or registered trademarks are properties of their respective owners.

Click here to see all recent news from this company

ORLANDO, FL–(Marketwire – October 18, 2010) –  GARTNER SYMPOSIUM/ITxpo — Mezeo Software (www.mezeo.com), the leading provider of a deployable cloud storage platform, today announced Gluster (www.gluster.com), the leading provider of open source storage solutions, as a Mezeo Ready Solution Partner. As a Mezeo Ready solution, the Gluster Storage Platform enables organizations using a Mezeo-enabled private, hybrid or public storage cloud to realize the cost, scalability and performance benefits of the Gluster Storage Platform. The Gluster Storage Platform is an open source, scale-out storage solution that runs on commodity hardware and simplifies the task of managing unstructured data at cloud-scale. Storage resources are aggregated into a single pool under a global namespace providing virtual storage that scales elastically. 

“We welcome Gluster as a Mezeo Ready Partner, and believe that our customers will be excited about being able to deploy petabyte-scale storage in a Mezeo cloud in just a matter of minutes,” said Mezeo President and CEO Steve Lesem. “Gluster’s modular design makes it highly scalable and flexible, which is ideal for anyone needing to move large amounts of unstructured data into the cloud.”

“We share Mezeo’s interest in making it easy to deploy high-performance storage clouds that deliver on the promise of reduced costs and simplified manageability,” said Ben Golub, CEO at Gluster. “We deliver the ability to store large amounts of data as well as the ability to respond to dynamically changing demands and workloads. This is especially important for our customers in industries such as Web applications, digital media and healthcare.”

Launched in June, the Mezeo Ready Program provides an ecosystem for service providers, developers, cloud gateway providers and technology partners all focused on delivering Mezeo-enabled cloud storage solutions.

With Mezeo, enterprises can implement a secure, private cloud, and IT Service Providers can rapidly monetize a branded cloud storage service offering. Mezeo features end-to-end encryption, advanced file sharing and collaboration, content tagging and access anywhere with white label Web 2.0, native Windows® desktop, iPhone and BlackBerry® clients. Mezeo is easy to deploy, multi-tenant, and highly scalable and secure, with REST Web Services APIs for platform extensibility.

Mezeo will be showcasing the Mezeo Cloud Storage Platform in booth 1029 at the Gartner Symposium/ITxpo 2010, continuing through October 21^st in Orlando, Fla.

Follow Mezeo on Twitter: http://twitter.com/mezeo.

About Gartner Symposium/ITxpo
Gartner Symposium/ITxpo is the IT industry’s largest and most strategic conference, providing business leaders with a look at the future of IT. For more than 10,000 IT professionals from the world’s leading enterprises, Gartner’s annual Symposium/ITxpo events are key components of their annual planning efforts. Attendees rely on Gartner Symposium/ITxpo to gain insight into how their organizations can use technology to address business challenges and improve operational efficiency. 

About Gluster
Gluster delivers an open storage software platform focused on simplifying the task of storing and managing the explosive growth of unstructured data. Our scale-out storage platform runs on commodity hardware scaling out in building block fashion from a few terabytes to multiple petabytes to meet the most demanding capacity and performance needs at a fraction of the cost of traditional systems. Gluster Storage Platform uses a unified global namespace to virtualize disk and memory resources into a single shared pool that is centrally managed. Our scalable NAS solutions address the needs of traditional data centers, shared storage for virtual server environments, and both public and private storage clouds. Gluster Storage Platform is used in a wide range of industries including digital media delivery, healthcare, internet, energy, and biotech. Gluster is privately-held and headquartered in Milpitas, California. For more information, visit www.gluster.com.

About Mezeo Software
Mezeo is the industry’s leading provider of a deployable platform for cloud storage. Service-enabled, the Mezeo platform is easy to deploy, multi-tenant, highly scalable and secure, with the Mezeo Cloud Storage API and Interoperability API for platform extensibility. With Mezeo, IT Service Providers can rapidly monetize Storage as a Service with a branded offering, and large enterprises can implement a secure, private cloud with clients for the desktop, Web, BlackBerry® and iPhone. Mezeo was named in CRN’s list of the Top 25 Coolest Emerging Vendors of 2010. For more information, visit www.mezeo.com. 

ALISO VIEJO, CA–(Marketwire – October 18, 2010) –  Enclarity Inc., a leading healthcare information solutions company, today announced the addition of ProviderPoint^® Web Services to its portfolio of hosted solutions. ProviderPoint Web Services gives payers an additional option for updating individual provider records in real-time. This Software as a Service (SaaS) solution uses a secure connection between the payer’s and Enclarity’s servers to automatically update one or more records at a time.

“Typically, a health insurance payer submits provider records to Enclarity for data cleaning and augmentation via a regularly scheduled batch process,” said Stephanie Rose-Belcher, vice president of payer solutions, Enclarity. “Using ProviderPoint Web Services, we now can update records on the fly. With our newest solution, customers are able to save time, money and get updates at the speed of their business.”

How it Works
The payer generates a provider output record that needs verification, augmentation and/or correction, and sends the data through Enclarity’s web service technology for processing. Enclarity ProviderPoint processes the record as soon as it is received, and the updated information is returned within seconds to the client’s system. Then, the client’s system applies the verified, corrected data along with augmentation of additional elements to the provider record. To assure speed and quality, Enclarity ProviderPoint Web Services uses system-to-system processing featuring industry-standard Simple Object Access Protocol (SOAP) message that can be uploaded into any application.

For more information about Enclarity ProviderPoint Web Services, listen to our latest podcast or visit our solution page at http://www.enclarity.com/ppws.php.

About Enclarity
Enclarity^® solves healthcare’s provider information problem. The company delivers correct, current and comprehensive provider information solutions by blending thousands of data sources, advanced analytics and healthcare expertise. As a result, its clients improve results in many areas, including claims processing, provider directories, regulatory compliance and market analysis. Named one of the Top 100 private technology companies in North America by Red Herring magazine and awarded the Global Healthcare Information Technology Excellence Award by Frost & Sullivan, Enclarity is headquartered in Aliso Viejo, Calif. For more information, visit www.enclarity.com.

Click here to see all recent news from this company

BOSTON, MA–(Marketwire – October 18, 2010) –  Shareable Ink, the leading provider of enterprise?grade digital pen and paper applications for healthcare, today announced the general availability of its newest solution, Shareable Ink Analytics™ for Anesthesia. The business intelligence module is a valuable extension of Shareable Ink Anesthesia Record™ that automatically extracts clinical, quality, and efficiency?related data from paper anesthesia records. Real?time access to information helps improve outcomes and operations.

Shareable Ink Analytics enables hospitals and groups to analyze 100 percent of charts without labor?intensive manual chart reviews and data extraction. The new solution incorporates dashboards and drill?down reports for a variety of clinical and administrative metrics, including Surgical Care Improvement Project (SCIP) measures, anesthesia turnover times, and on?time case starts. Managers can easily pinpoint areas of improvement and compare performance across facilities and providers by viewing increasingly granular data: from the health system level to individual outliers and cases of interest.

“More than 90 percent of anesthesia recordkeeping is paper?based. As a result, operational data has been traditionally difficult, if not impossible, to aggregate and understand,” said Stephen S. Hau, President and CEO of Shareable Ink. “The Shareable Ink approach enables anesthesia providers to continue their familiar documentation method, while providing all the analytical benefits of electronic data output.”

“With 360 providers in 28 different hospitals and ASCs, Shareable Ink Analytics gives us the ability to instantly review, report, and manage real-time performance,” said Brian Woods, MD, Chief Medical Officer of NorthStar Anesthesia. “From patient clinical outcome measures to OR throughput efficiency assessments, we can now know exactly how we are doing at the enterprise, facility, and individual provider level.”

Shareable Ink Analytics will be featured at the American Society of Anesthesiologists’ Annual Meeting — ANESTHESIOLOGY 2010 — in San Diego from October 16 through October 20. To learn more, please stop by the Shareable Ink booth (#3930).

About Shareable Ink
Shareable Ink helps healthcare organizations of all sizes transition to electronic health records without disruption to workflow or burdensome IT projects. Its software platform incorporates enterprise?grade digital pen and paper technology featuring Anoto functionality. Shareable Ink enables clinicians to continue documenting in the fastest, most natural manner, while populating the EHR with discrete data, as if typed with a keyboard. Built?in analytics give hospitals and practices insight into their operations — from a clinical, quality and efficiency standpoint — all previously inaccessible from traditional paper records. For additional information, visit www.shareableink.com.

DENVER, CO–(Marketwire – October 18, 2010) –  Omni Bio Pharmaceutical, Inc. (“Omni Bio”) (OTCBB: OMBP) today announced that the first patient has been infused in its FDA-cleared Phase I/II human clinical trial of Alpha-1 antitrypsin (“AAT”) in recently diagnosed Type 1 diabetics at the Barbara Davis Center for Childhood Diabetes at the University of Colorado Denver Anschutz Medical Campus.

The Phase I/II clinical trial is evaluating the potential of AAT to halt or reduce the deterioration of islet beta cells that causes Type 1 diabetes. While Type 1 diabetics will experience islet beta cell destruction, the trial evaluates whether AAT treatment may help stop the course of disease in newly diagnosed diabetics who may have remaining islet beta cells.

AAT is an FDA-approved, off-patent drug with an almost 20-year safety track record as an approved treatment in the approximately $400 million market for emphysema in AAT deficient patients. Omni Bio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market.

Dr. Charles A. Dinarello, Acting Chief Executive Officer of Omni Bio, stated, “Following promising preclinical evidence of AAT in Type 1 diabetes, we filed with the FDA to move right into a Phase I/II clinical trial in newly diagnosed Type 1 diabetic patients. We are encouraged by the agency’s clearance to advance from the preclinical stage into actual patients, and the initial patient infusion is a major milestone for Omni Bio. If AAT is effective in disrupting the deterioration of the islet beta cells, we believe that we may be able to expedite our time to market in Type 1 diabetes, given the significance of the unmet medical need and the supportive safety track record of AAT in its currently approved indication.”

Dr. Dinarello continued, “Type 1 diabetes is a large and attractive market for Omni Bio, and we believe that our method of use patent applications surrounding AAT further position us to capitalize on this opportunity to deliver shareholder value while improving treatment for up to 20,000 Type 1 diabetics diagnosed in the U.S. each year.”

About the Phase I/II Trial
The FDA-cleared Phase I/II human clinical trial of AAT in recently diagnosed Type 1 diabetics is underway at the Barbara Davis Center for Childhood Diabetes at the University of Colorado Denver Anschutz Medical Campus. Patients will receive an eight-week treatment course of AAT infusions, followed by two years of monitoring. Targeted enrollment is initially 15 patients, and may be expanded to up to 50 patients pending positive data in critical measurements.

About AAT in Type 1 Diabetes
Type 1 diabetes is an autoimmune disease in which the immune system attacks insulin-producing beta cells in the pancreas, which are necessary for the body to maintain proper blood glucose levels. Not all beta cells are typically destroyed at the time of diagnosis, and between 15-40% remain healthy and able to produce insulin. Preserving these remaining beta cells is the goal of AAT therapy in Type 1 diabetics, as their ability to naturally produce even small amounts of insulin can improve blood sugar control, simplify daily management of diabetes, and reduce the risk of long term complications.

About Omni Bio Pharmaceutical, Inc.
Omni Bio Pharmaceutical, Inc. (www.omnibiopharma.com) is an emerging biopharmaceutical company formed to acquire, license, and develop existing therapies for indications with substantial commercialization potential. Omni Bio’s core technology and pipeline are based on issued and pending patents licensed from the University of Colorado Denver (“UCD”) and a privately held corporation surrounding the broader therapeutic potential of currently marketed therapies. One of Omni Bio’s lead development programs is evaluating an FDA-approved, off-patent drug, AAT, for the treatment of Type 1 diabetes. Novel discoveries made at UCD indicate that AAT has the potential to address a variety of indications in the areas of bacterial and viral disorders, biohazards, diabetes and transplant rejection.

Omni Bio is led by Acting CEO Dr. Charles Dinarello, Professor of Medicine in the Division of Infectious Diseases at UCD. Dr. Dinarello is considered a founding father of cytokine biology. For additional information, please visit www.omnibiopharma.com.

Forward-Looking Statements
Some of the statements made in this press release are forward-looking statements that reflect management’s current views and expectations with respect to future events, including the clinical trial. These forward-looking statements are not a guarantee of future events and are subject to a number of risks and uncertainties, many of which are outside our control, which could cause actual events to differ materially from those expressed or implied by the statements. These risks and uncertainties are based on a number of factors, including but not limited to the business risks disclosed in our SEC filings, especially the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2010. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

MISSION, KS–(Marketwire – October 18, 2010) –  (Family Features) Tooth enamel is the hard, outer layer of the tooth that helps protect the tooth from extreme temperatures and the erosive effects of acids.

At times, enamel gets stained and weakened by things you consume such as coffee, tea, fruit juice, soda, wine or cigarettes. Fortunately, there are things you can do to help keep your smile white and your enamel strong.

• Floss and brush daily with a fluoride toothpaste.
• See a dentist every six months for a cleaning and checkup.
• Reduce your intake of highly acidic foods and drinks or rinse with clear water after eating or drinking these things.

Now, Arm & Hammer offers a way to whiten your teeth and strengthen your enamel conveniently and inexpensively. New Arm & Hammer Whitening Booster Plus Enamel Strengthening is designed to provide safe, effective whitening and enamel strengthening without adding an extra step to your oral-care routine. Simply apply over your favorite fluoride toothpaste and brush as normal. Featuring a peroxide formula with Liquid Calcium, this provides teeth with daily whitening and enamel strengthening when used as directed.

Taking good care of your teeth with healthy habits and easy-to-maintain routines will help keep your smile strong and vibrant.

MISSION, KS–(Marketwire – October 18, 2010) – (Family Features) Only about a third of American women are meeting their fruit and vegetable intake recommendations, according to the Centers for Disease Control and Prevention. And that means they are likely missing out on potentially important breast and ovarian health benefits. Along with vitamins, minerals and fiber, fruits and vegetables contain a type of phytonutrient called carotenoids, which research suggests help support women’s health including breast and ovarian health. 

Based on a new report called America’s Phytonutrient Report: Women’s Health by Color, older women have total carotenoid intakes 20 percent greater than younger women after accounting for differences in caloric intake. Similar to the original America’s Phytonutrient Report: Quantifying the Gap which found that on average eight out of 10 American adults are falling short on phytonutrient consumption, the new report revealed a troubling shortfall, this time among women and carotenoids. America’s Phytonutrient Reports are released by The Nutrilite Health Institute, a worldwide collaboration of experts who are dedicated to helping people achieve optimal health — through research, education, and practical, personalized solutions. Nutrilite is the world’s leading brand of vitamin, mineral, and dietary supplements, based on 2008 sales.

Carotenoids are compounds that give fruits and vegetables their vibrant colors, which research suggests may offer breast, ovarian and other health benefits for women. Using NHANES energy-adjusted data to compare the diets of women 45 years and older with those younger, the report finds that many women of all ages lack carotenoid-rich foods in their diet, but the relative magnitude of the “carotenoid gap” is greater among women less than 45 years old as compared to older women.

“This points to a troubling phenomenon where younger women may be missing some of the benefits of consuming more carotenoid rich fruits and vegetables, and yet calorie for calorie, older women are eating more of these important nutrients,” said Keith Randolph, Ph.D., Technology Strategist for Nutrilite. 

Powering Up Produce
Choosing to increase the amount of the fruit and vegetables richest in carotenoids is important for long-term preventative health among women. While foods like spinach, tomatoes and carrots are certainly part of a healthy diet, there are opportunities for women to choose a wider variety of produce.

“It’s concerning that so many American women lack a variety of carotenoid-rich foods in their regular diets,” says Amy Hendel, Nutrilite’s Phytonutrient Coach. “By selecting the most carotenoid-rich produce choices, women can purposefully increase their carotenoid and phytonutrient intakes which can impact health significantly as they age.”

Hendel, a registered physician assistant and health/wellness expert, offers these easy substitutions to “power up” your plate and add new flavors to your meal plan:

Green: A serving of cooked kale provides triple the amount of lutein/zeaxanthin as a serving of raw spinach.
Red: A serving of guava delivers more than one and a half times the lycopene in a raw tomato.
Yellow/Orange:

• A serving of sweet potatoes has nearly double the beta-carotene as a serving of carrots.
• A serving of carrots delivers four times the amount of alpha-carotene as a serving of winter squash.
• A serving of fresh papaya has roughly 10 times the beta-cryptoxanthin found in an orange.

Hendel adds, a good goal for most individuals is to consume 10 servings of fruits and vegetables daily, with an emphasis on quality, not just quantity. If this proves challenging, consider a natural, plant-based dietary supplement which includes phytonutrients such as carotenoids.

For more information about Nutrilite Nutritional Supplements and to get more practical tips, visit www.nutrilite.com/color.

MISSION, KS–(Marketwire – October 18, 2010) – (Family Features) As expectant and new moms know, having a baby is one of the most wonderful experiences, but it can also be overwhelming. First-time mothers and veteran moms alike have questions about keeping their babies safe and healthy. They’re eager to learn about important areas such as nutrition, immunization, and safe sleep. 

To address their questions and concerns, the National Healthy Mothers, Healthy Babies Coalition (HMHB) developed text4baby. This free mobile educational service promotes a healthy pregnancy and a healthy start in life for all babies.

With more than 1.3 trillion text messages sent and received in the U.S. in 2009, it makes sense to deliver vital health information through mobile technology. Currently in the United States, more than 500,000 babies — 1 in every 8 — are born prematurely. An estimated 28,000 children die before their first birthday, a rate among the highest in the industrialized world. Premature infants come into the world with unique health needs that can mean lifelong challenges. Text4baby helps to address these issues by allowing timely and useful information to be distributed to help give babies the best possible start in life. 

While not everyone has access to the internet, 90 percent of Americans have a mobile phone. Text messaging is soaring in popularity and can be especially helpful in reaching first-time mothers in typically underserved populations.

How It Works
By texting BABY (or BEBE for Spanish) to 511411, a woman will be signed up to receive three free text messages each week that are timed to her due date or baby’s date of birth. These messages focus on a variety of topics critical to maternal and child health, including birth defects prevention, immunization, nutrition, seasonal flu, mental health, oral health, and safe sleep. Text4baby text messages also connect women to prenatal and infant care services and other resources.

Wireless carriers are waiving text messaging fees for the initiative, so enrollees opting in to receive text messages will incur no charges. Even users without a text messaging plan or limited texting per month will receive these messages for free.

To date, text4baby has sent more than five million English and Spanish text messages to more than 83,000 pregnant and new mothers. According to text4baby enrollment numbers, 96 percent of participants would recommend the service to a friend. 67 percent of the enrollees are receiving information about pregnancy, while the remaining 33 percent are getting information about newborns. 

“For those of us dedicated to health education, knowing that text4baby messages are reaching the women who are most in need of them is incredibly powerful and exciting,” said Judy Meehan, CEO of the National Healthy Mothers, Healthy Babies Coalition. “Thanks to our partnership with CTIA-The Wireless Foundation and the mobile carriers, more than 5 million valuable health messages have been put in the hands of thousands of pregnant women since our February 4 launch.”

Text4baby is made possible through a public-private partnership that includes more than 350 organizations. The program’s founding partners include CTIA-The Wireless Foundation.

For more information, or to sign-up to receive the free text messages, visit www.text4baby.org.

MENLO PARK, CA–(Marketwire – October 18, 2010) –  Depomed, Inc. (NASDAQ: DEPO) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at the 17^th Annual Meeting of NewsMakers in the Biotech Industry Conference on Friday, October 22, 2010 at 9:30 am EST, and at the Oppenheimer 21^st Annual Healthcare Conference on Wednesday, November 3, 2010 at 2:45 pm EST, both in New York City.

The company will be webcasting its presentation and interested parties can access the live or archived presentation for up to 90 days on the company’s website at www.depomed.com.

About Depomed
Depomed, Inc. is a specialty pharmaceutical company with one product candidate through Phase 3 clinical development, another in Phase 3 clinical development, two approved products on the market and other product candidates in its early stage pipeline. Product candidate DM-1796 has completed Phase 3 clinical development and has been licensed to Abbott Products Inc. A New Drug Application for DM-1796 was accepted by the FDA in the second quarter of 2010. Product candidate Serada^® is in Phase 3 clinical development for menopausal hot flashes. GLUMETZA^® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform^® drug delivery technology, which is designed to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of Acuform-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. Additional information about Depomed may be found on its website, http://www.depomed.com.

CENTERVILLE, MA–(Marketwire – October 18, 2010) –  UV Flu Technologies, Inc. (OTCBB: UVFT) (the “Company”) is pleased to announce that it has been selected as the only air purification medical device to be listed in the Infection Control Segment of the prestigious UK-based opinion and analysis industry publication “Public Service Review.” In this, our second appearance for 2010, the Company offers an informative profile within the magazine as well as a full page back cover advertisement.

The Public Service Review features contributors that include UK and foreign ministers, senior civil servants, experts and academics discussing the latest initiatives and projects along with case studies and comments on best practices affecting public sector initiatives worldwide.

“The spread of airborne bacteria and infectious diseases in the United Kingdom, in some areas, is reaching epidemic levels,” said Jack Lennon, President of UV Flu Technologies. “There is more than a 10% risk of becoming infected by HAI’s, or hospital associated infections, in many of the medical facilities in the United Kingdom, making Infection Control a much more visible issue than it is in this country. Being selected for inclusion by the ‘Review’ as the only laboratory tested device capable of killing these bacterial superbugs is a distinct honor.”

Mr. Lennon continued to say, “There is a great deal of attention in the UK, and in the United States, on the spread of MRSA, a bacteria resistant to antibiotics and estimated to kill tens of thousands of people every year, and in many instances affects people who have been in a medical facility. In fact, over the last 4 weeks an outbreak of Legionnaires Disease in South Wales garnered international attention as three deaths were reported, and a number of people were stricken. The world believed Legionnaires to no longer pose a threat, but experts believe it kills thousands of people yearly through improper diagnosis as pneumonia. The ViraTech UV-400 cost effectively and efficiently kills these airborne bacterial strains, and it was this that led to our inclusion in this particular issue.”

Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The product also is highly effective in reducing odors and VOC’s, or Volatile Organic Compounds, such as acetone, benzene and formaldehyde. ViraTech UV-400 is a Class II medical device and is available without a prescription. 

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

UV Flu Technologies, Inc.
—————————–
John J. Lennon, President & CEO

Click here to see all recent news from this company

LAGUNA BEACH, CA–(Marketwire – October 13, 2010) –  The American Society of Bariatric Plastic Surgeons (ASBPS) today announced a partnership with RealSelf.com, a community that shares, discusses, and rates cosmetic services and procedures, that enables its 134 surgeon members to seamlessly participate and contribute to the growing online community.

The ASBPS delivers expert advice and educational resources on body contouring surgery with the goal of helping patients that have lost significant weight to find a knowledgeable and experienced plastic surgeon. This partnership significantly expands on the existing resources available to RealSelf.com visitors who anonymously seek authoritative counsel on post-surgical bariatric care and excess skin issues.

“For some patients, the euphoria — and associated health benefits — of significant weight loss may be tempered by the new realities of excess skin,” said ASBPS President Edward J. Domanskis, M.D., F.A.C.S. “This can be a highly personal issue, and before considering surgical options, many people first turn to online sources for education. RealSelf.com provides consumers with an easily accessible expert community, an open forum for discussion, and credible, of-the-moment resources. Our member surgeons look forward to sharing their knowledge to improve the quality of life for consumers seeking elective body sculpting surgeries.”

RealSelf.com includes thousands of first-hand accounts from past patients on hundreds of cosmetic services and skincare treatments, including Worth It ratings, cost, diaries of the experience, before and after photos, and videos. To date, board-certified doctors have posted more than 100,000 answers to consumer questions on RealSelf.

“Our bariatric surgery community on RealSelf.com has shown a marked increase in consumer interest, and we’re responding by ensuring visitors get timely, expert answers from leading medical authorities,” said Tom Seery, founder and president of RealSelf.com. “By aligning with ASBPS, we’re now providing access to the latest technologies and news on body sculpting surgery for consumers.”

About ASBPS

The American Society of Bariatric Plastic Surgeons was established by plastic surgeons that specialize in body contouring surgery specifically for patients that have lost significant amounts of weight through non-surgical means, such as diet or exercise, or through the various bariatric procedures. The goal of ASBPS is to help consumers find a knowledgeable and experienced plastic surgeon. Its members are all certified by the American Board of Plastic Surgeons and most are members of the American Society of Plastic Surgeons as well as the American Society of Aesthetic Plastic Surgery or the Canadian Society of Plastic Surgeons.

About RealSelf.com

RealSelf.com is the largest social media site for sharing information about cosmetic treatments, cosmetic dentistry, anti-aging, and skin health. Featuring real opinions, reviews, and ratings, as well as doctor Q&A and before and after photographs, RealSelf covers hundreds of topics including plastic surgery procedures such as Mommy Makeovers, breast augmentation, tummy tuck, and liposuction. The Seattle-based privately held company is angel funded. For more information, visit http://www.realself.com.

NORMAN, OK–(Marketwire – October 13, 2010) –  Access Plans, Inc. (OTCBB: APNC), a leading membership benefits marketing company, today announced the appointment of Charles Harris as President of America’s Health Care/Rx Plan Agency, Inc. (“AHCP”), the Company’s insurance marketing division and subsidiary. 

“We are very pleased to welcome Charles Harris to our management team,” commented Danny Wright, Chief Executive Officer of Access Plans, Inc. “He brings to our Company over 25 years of experience in the health insurance industry, where he has served in a number of management positions, and AHCP will benefit greatly from his exceptional overall understanding of the business. Charles’ solid marketing, accounting and compliance experience, in addition to his familiarity with AHCP, its founding management and the challenges that confront the industry today, make him uniquely qualified to lead AHCP.” 

Mr. Harris most recently served as President and Chief Executive Officer of National Health Insurance Company in Ft. Worth, Texas.

About Access Plans, Inc.

Access Plans, Inc. (OTCBB: APNC) is a leading membership benefits marketing company with two distribution channels. The Wholesale/Retail Plans distribution channel specializes in turnkey, private-label membership benefit plans that provide discount products and services, protection benefits, and retail services to more than one million customers in the United States and Canada. America’s Health Care/Rx Plans (“ACHP”), the Company’s Insurance Marketing distribution channel, is one of America’s largest independent agent networks and provides major medical, life and supplemental insurance products to individuals. 

The Company is headquartered in Norman, Oklahoma, and its common stock trades on the OTC Bulletin Board under the symbol “APNC”. For more information, visit the Company’s website at www.accessplans.com.

Forward-Looking Statement

This press release includes “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, Section 27A of the Securities Act of 1933, as amended, and pursuant to the “safe harbor” provision of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may relate to financial results and plans for future business activities, and are thus prospective. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed in, or implied by, such forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are competitive pressures, loss of significant customers, revenue mix, changes in pricing policies, delays in revenue recognition, lower-than-expected demand for the Company’s products and services, general economic conditions, and other risk factors detailed from time to time in the Company’s periodic reports and registration statements filed with the Securities and Exchange Commission. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995, and the Company assumes no responsibility for updating such forward-looking statements after the date of this release.

OAKBROOK TERRACE, IL–(Marketwire – October 13, 2010) – The Sullivan Group, a leading provider of clinician solutions to reduce medical errors and malpractice claims, launched its National Risk & Safety Collaborative today at the ASHRM Annual Conference. The Collaborative was created to extend The Sullivan Group’s proven framework for saving lives and reducing risk with evidence-based e-Learning, software, and services. Nationally known physicians who teach patient safety in high-risk areas of medicine were chosen as Collaborative Champions for their specialties.

The Sullivan Group is exhibiting this week at the American Society for Healthcare Risk Management’s 30^th Annual ASHRM Annual Conference and Exhibition, held October 13 – 16, 2010 in Tampa; they are located in booth #200. Dr. Dan Sullivan, president and CEO of The Sullivan Group, will be joined at ASHRM by Dr. Henry Lerner, Obstetrics Champion for the Collaborative, to discuss this new initiative with conference attendees.

Dr. Sullivan states, “Collection and analysis of 12 years of medical error data proved that there needs to be a deep, systemic change in medical systems and processes in order to keep patients safe and reduce medical errors at the point of care. We all know that missing a single detail can be lethal, so risk management must be real-time and occur at the bedside. With our National Risk & Safety Collaborative we are leveraging our success and proven methodology in emergency medicine to other high-risk practice areas.”

The National Risk & Safety Collaborative represents the culmination of Dr. Sullivan’s vision for a broad-based system solution to the national medical error and patient safety problem. Preventable medical mistakes and infections are responsible for about 200,000 deaths in the U.S. each year, according to an investigation by the Hearst media corporation, which published its findings in “Dead by Mistake” in 2009.(i) The Sullivan Group’s successful Emergency Medicine solutions have been shown to reduce medical errors by up to 50%, which in turn decreases malpractice claims and associated financial losses. 

These proven solutions have been implemented at over 600 U.S. hospitals, physician groups, and risk retention groups (RRGs) nationally. Three fundamental components to The Sullivan Group’s “Risk, Safety, Quality Cycle” are incorporated in all of the solutions developed by the Collaborative. These include:

• Web-based risk and safety education covering the spectrum of high-risk care
• Bedside clinical decision support tools
• Clinical performance evaluation relative to evidence-based best practices

Collaborative Champions
 Renowned doctors have joined the National Risk & Safety Collaborative with the goal of expanding The Sullivan Group’s solutions for reducing medical errors and malpractice claims into the areas of obstetrics, surgery, hospitalist medicine, pediatrics, family practice, stroke, internal medicine, medical-legal, emergency ultrasound, toxicology, and triage. Each Champion is working with The Sullivan Group to create a scalable solution to the patient safety and risk issues for his or her specialty and build it into the fabric of delivery of medical care. This is not a single “one size fits all” solution. Each Champion will work with The Sullivan Group to develop a multi-faceted, patient-centric approach that is specific to his or her specialty and is focused on the point of care.

Dr. Lerner is developing Obstetric solutions building on The Sullivan Group framework. He explains, “Having practiced obstetrics for over 30 years, delivered over 9,000 babies, and reviewed over 300 obstetrical medical malpractice cases, I have developed a sense of which clinical practices most often lead to good outcomes and low liability and which practices do not. My goal is to share this experience in an organized, programmatic way with obstetricians and obstetrical units across the country.”

The Champions involved in the Collaborative include:

• Dan Sullivan, MD, JD, FACEP – Emergency Medicine and Medical-Legal
• Henry Lerner, MD – Obstetrics
• Geoffrey A. Machin, MD, PhD – Fetal and Placental Pathology
• Steven Selbst, MD – Pediatric Emergency Medicine
• Fred Callahan, MD – Stroke
• Scott Allen Kale, MS, JD, MD – Internal Medicine
• Paul Sierzenski, MD, RDMS, FAAEM, FACEP – Emergency Ultrasound
• Leon Gussow, MD, FACMT, RDMS – Toxicology
• Shelley Cohen, RN, MSN, CEN – Triage
• Steven Pantilat, MD – Hospitalist Medicine

The Sullivan Group has created a guide on the National Risk & Safety Collaborative, including full biographies of the Champions. For more information on The Sullivan Group’s approach for reducing medical errors and malpractice claims, view this three minute video: www.thesullivangroup.com/images/flash.html

Note to Editors: If you are interested in setting up an in-person meeting with Dr. Dan Sullivan or with Dr. Henry Lerner during ASHRM or a telephone interview after the show, please contact Maria Doyle at [email protected] or 781-964-3536.

About The Sullivan Group
 The Sullivan Group provides software and services solutions to help reduce medical errors and malpractice claims across the spectrum of high-risk clinical care. The Sullivan Group’s clients — hospitals, physician groups, and RRGs — have reduced malpractice claims and financial losses due to medical errors by up to 50%. The Sullivan Group achieves these results by leveraging an evidence-based approach to integrate extensive clinical knowledge with technology focused on the point of care. For more information, visit www.thesullivangroup.com.

(i) http://www.hearst.com/press-room/pr-20090809b.php

id=”nav_links”>

DALLAS, TX–(Marketwire – October 13, 2010) – New Century Hospice, a provider of hospice care to patients in nine centers located in Texas, today announced that it has closed $20M in Series A financing, led by Scale Venture Partners and Petra Capital Partners. New Century Hospice will use this new financing to continue its expansion of standalone hospice care centers located in Texas and neighboring Southern states. With the completion of this financing, Mark Brooks and Lou Bock, both Managing Directors with ScaleVP, and David Fitzgerald, General Partner with Petra Capital, join the Board.

New Century Hospice owns nine hospice companies in Texas under the operating names of Century Hospice, Cosmos Hospice, Heritage Care Hospice, Paragon Hospice and Angel Heart Hospice.

“I started this company with the belief that providing patients with high-quality, end-of-life care is both good for patients and their families and is cost-effective as well,” said David Gasmire, founder and CEO of Century Hospice. “Lou, Mark and David are experienced investors in companies that deliver medical care in a clinical situation. They understand how to scale this type of business successfully, while keeping care for patients the top priority. I look forward to working with them as we expand the company.”

Patients served by hospice typically have a life expectancy of six months or less, and the treatment is focused on palliation or comfort care for the patient and the family. The hospice approach to care is called “interdisciplinary,” because it involves the participation of many healthcare professionals, who are focused on addressing medical, spiritual, psycho-social and personal needs of patients and their families. The goal of this approach is quality of life for both patients and their families. The Medicare Hospice Benefit, enacted in 1983, also provides for medications, equipment and supplies related to the patient’s diagnosis.

“ScaleVP has a history of successful investments in healthcare service companies like New Century Hospice, where demographic trends and superior outcomes at lower costs drive growth,” said Mark Brooks, Managing Director with ScaleVP. “It is an honor to be working with David and the team at Century Hospice to expand their care centers.”

David Fitzgerald, General Partner with Petra Capital commented, “Hospice care will play an increasingly important role as more physicians begin to view hospice as the most appropriate option for patients with a terminal diagnosis. In our view, hospice care allows patients and their families to address the emotional and physical challenges of end of life care with the support of an interdisciplinary team in the most appropriate care setting. We are pleased to have the opportunity to partner with such an outstanding management team, led by David Gasmire, and look forward to helping New Century Hospice achieve its growth plans.”

About Scale Venture Partners
Based in Foster City, California, the ScaleVP team is a long-standing partnership with a consistent, top quartile track record of returns for the past decade. ScaleVP’s market-tested investment strategy, extensive operating networks and go-to-market expertise help identify and build successful portfolio companies in technology and healthcare markets. The ScaleVP team’s collaborative and active approach provides entrepreneurs a competitive advantage for growth and category leadership. Representative portfolio companies include AlimeraSciences, EverydayHealth, ExactTarget, Frontbridge, IPC TheHospitalist Company, mBlox, Monolithic Power Systems, National Healing, NComputing, Omniture, Orexigen, ScanSafe, and Zogenix. For more information, visit www.scalevp.com.

About Petra Capital Partners
Petra Capital Partners, LLC is a private equity firm based in Nashville, Tennessee. The firm is actively investing its second SBIC fund, Petra Growth Fund II, which has $160 million of available capital to invest. Its previous funds under management total $130 million. Petra provides non-control subordinated debt and/or preferred stock to high growth companies for expansion, acquisition, buyout, refinancing or recapitalization in partnership with the founding management team. Petra seeks to invest up to $15 million in growth companies that possess a minimum of $10 million in revenue and positive EBITDA at the time of investment. The fund targets business, healthcare and information technology services companies. For more information, please visit Petra’s website at www.petracapital.com or call (615) 313-5999.

About New Century Hospice
Based in Dallas, Texas, New Century Hospice is a leading provider of hospice services to patients, families and healthcare providers. The Management Team of Century Hospice has, combined, over 50 years of hospice experience. At New Century Hospice, we believe that quality care provides quality time for our patients and their families. For more information, please contact: www.centuryhospice.com.

TUSTIN, CA–(Marketwire – October 13, 2010) – Provista Life Sciences and Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today the validation study results of a blood test for early detection of lung cancer and Provista’s plans to broadly introduce this new test to market.

The study completed the requisite analyses and data evaluation needed to validate Provista’s test, based on Radient Pharmaceutical Corporation’s antigens for fibrinogen degradation products (FDP), successfully detects lung cancer with a high degree of accuracy. The study included men and women between 20-76 years of age. The data generated in this final study proved consistent with previous findings and produced positive clinical performance marks of 87% sensitivity; 95% specificity; and an ROC Accuracy of 0.97. By industry standards the study proved very successful and will serve as the cornerstone to Provista’s efforts to introduce a new lung cancer detection assay branded LC Sentinel™ to market. Provista intends to introduce LC Sentinel™ as a CLIA Laboratory Developed Test (LDT) for use in high-risk lung cancer patient populations in the U.S. by the end of the fourth quarter 2010 through its standard clinical channels that include physicians, medical clinics and hospitals. The company expects to seek FDA registration for LC Sentinel™ in 2011.

According to Provista CEO William Gartner, “We are exceptionally pleased at the test results and will aggressively market and commercialize this important and potentially life-saving lung cancer test beginning in the fourth quarter 2010.” Gartner also expressed high praise for the quality of the RPC’s manufacturing facilities and chemicals indicating the Company is pleased to be an exclusive partner of RPC in the development of the test. In conjunction with today’s announcement, RPC and Provista also announced the two Companies will execute an exclusive lab partnership agreement where Provista Life Sciences will purchase RPC reagents exclusively for the development of LC Sentinel™.

The American Cancer Society’s estimates of the impact of lung cancer in the U.S. during 2009 include approximately 219,000 new cases (both non-small cell and small cell) and 159,000 deaths resulting from the disease, accounting for 28 percent of all cancer deaths. Lung cancer is the leading cause of cancer death among both men and women — 62% of those diagnosed in late stages die within 5 years. Provista estimates there are approximately 18 million high-risk patients who stand to benefit from the test’s US introduction. 

According to Mr. Douglas MacLellan, Executive Chairman and CEO of RPC, “The detection benefit observed in this study represents a meaningful additional to tests available today. We are very encouraged by the potential benefit of this test to patients who are facing the deadly threat of lung cancer. As previously announced, RPC is actively engaged in acquisition negotiations with Provista and with the success of the deal; we expect to combine both companies to achieve a leadership presence in the global cancer diagnostics market.”

On September 27, 2010 RPC signed an extension of its original agreement dated July 13, 2010 to merge with Provista Diagnostics Inc., making the agreement between Provista Diagnostics and Radient Pharmaceuticals effective through December 31, 2010. Both Companies have confirmed continued interest in the merger and to pursue completion of the deal within a timeframe that suits the needs of both Companies and shareholders.

For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

For additional information on Provista Diagnostics Inc and its diagnostic portfolio, visit the company’s website at www.ProvistaLS.com. For additional information contact Donald Weber, COO, or William Gartner, CEO, at 602.224.5500.

About Provista Life Sciences:
Provista Life Sciences is a biotechnology diagnostics development and Commercialization Company located in Phoenix, AZ, the Company provides the scientific and operating management resources to rapidly advance the development and introduction of novel diagnostics technologies into the domestic and global marketplace. For more information, visit the company’s Web site at www.ProvistaLS.com or call 1.602.224.5500.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its Onko-Sure® In Vitro Diagnostic cancer test. The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve patient outcomes. Radient Pharmaceutical’s current Onko-Sure® cancer testis used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – October 7, 2010) – For insulin dependent diabetics it has been the ultimate treatment goal: a pump and monitor combination that would not only read glucose levels but also determine how much insulin to deliver, and administer it. In recent years, such products have become available and given the growing patient population, this should be a high-growth area in the IVD market, according to healthcare market research publisher Kalorama Information, in its latest report on the IVD industry, “Worldwide Market for In Vitro Diagnostic Tests, 7^th Edition.”

Kalorama estimates that in 2009, continuous blood glucose systems by three companies, Medtronic, Dexcom and Insulet, generated product sales of close to $200 million, as compared to approximately $100 million in 2008. This is high revenue growth for testing markets, and growth could increase in the future given an expanding patient population and increasing acceptance in healthcare, according to Kalorama Information.

“This is a hot and very competitive area and companies are demonstrating well above average growth for IVD products,” said Shara Rosen, lead diagnostic analyst for Kalorama Information and author of the report. “Most importantly, it’s an underserved market.”

Fewer than 30% of U.S. type 1 diabetes patients using insulin pumps and less than 1% of type 2 diabetes patients who use insulin pumps are currently using continuous monitors. CMS assigned unique codes and reimbursement rates for continuous glucose monitoring. 

According to Rosen, the unmet demand for this type of system is best illustrated by DexCom’s revenue track record. Since starting at just $2 million in 2006, sales have virtually doubled each of the past three years.

Kalorama’s report lists at least 10 devices that are already available and at least as many more in development. According to the report, not all of these developed products will be able to succeed. Smiths Medical’s (St. Paul, MN) recent exit from the market indicates just how competitive this segment has become, even when partnered with IVD veteran Abbott Diabetes Care. Smiths Medical (formerly Deltec, Inc.) was one of the first companies to commercialize a continuous BGM system. In June 2004, the company received FDA clearance to market the CozMore Insulin Technology System and in spite of continued improvements, the product failed to gain significant market share. 

Point-of-Care, or POC diagnostic tests are just one area covered in Kalorama Information’s extensive review of the in vitro diagnostic testing industry, “Worldwide Market for In Vitro Diagnostic Tests, 7^th Edition.” The report can be found at:
http://www.kaloramainformation.com/redirect.asp?progid=79735&productid=2613362.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

BERKELEY, CA–(Marketwire – October 7, 2010) – Berkeley Bionics™, developer and maker of bionic exoskeletons that augment human strength, endurance and mobility, today unveiled eLEGS, a wearable, artificially intelligent, bionic device that powers paraplegics up to get them standing and walking.

eLEGS was unveiled at a press conference today in San Francisco by Berkeley Bionics’ CEO, Eythor Bender, who explained that the company’s mission is to provide people with unprecedented mobility options. “Many of the 6 million Americans who live with some form of paralysis today were highly active and at the top of their game when they sustained their injury. As they research their options for increased mobility, they discover that wheelchairs are pretty much it. This has been the only alternative — their only hope — for nearly 500 years,” he said. “We want to enhance their independence and freedom of movement,” he added, “and with eLEGS, they can stand up and walk for the first time since their injury.”

“As a wheelchair user, I experience the multiple health and fitness benefits of mobility from the standing position. I can’t wait to share this alternative with other individuals,” shared eLEGS tester and a partial quadriplegic herself, Dr. Suzy Kim, an assistant clinical professor at the Dept. of Orthopaedic Surgery, Physical Medicine & Rehabilitation, UCI Medical Center, as well as director, Clinical Spinal Cord Injury Program & Scientific Liaison for Reeve-Irvine Research Center. “The application of eLEGS will revolutionize the field of neurologic rehabilitation from the hospital to the home setting.”

Initially, the device will be offered to rehabilitation centers for use under medical supervision, and can be adjusted to fit most people between 5’2 and 6’4″ and weighing 220 lbs or less, in a matter of minutes. Users must be able to self-transfer from their wheelchair. Simple Velcro straps, backpack-style clips, and shoulder straps secure eLEGS to the user, over their clothing and shoes, and with a little practice, users can put eLEGS on and take it off in a minute or two.

eLEGS provides unprecedented knee flexion, which translates into the most natural human gait available in any exoskeleton today, making it better equipped to handle mixed terrains. It is also relatively quiet while in operation. Walking speeds depend on each patient’s aptitude and condition, but speeds in excess of 2MPH can be attained, and speeds can be varied. The device is battery-powered and employs a gesture-based human-machine interface which — utilizing sensors — observes the gestures the user makes to determine their intentions and then acts accordingly. A real-time computer draws on sensors and input devices to orchestrate every aspect of a single stride.

Clinical trials will commence early next year at select rehabilitation clinics in the United States. A limited release of eLEGS is scheduled during the second half of 2011 at several of the most respected rehabilitation facilities around the country. At that time, eligible patients will have the opportunity to enroll in a medically-supervised eLEGS gait training program, working with their physical therapist. Therapists will undergo training in order to become eLEGS-certified prior to assisting patients.

Berkeley Bionics developed the first practical exoskeleton and the first untethered exoskeleton in the world. Lockheed Martin Corporation entered into a licensed agreement with Berkeley Bionics in January 2009 and is currently productizing the Human Universal Load Carrier (HULC™). HULC’s users can carry up to 200 lbs for hours and over all terrains.

About Berkeley Bionics

Berkeley Bionics (www.berkeleybionics.com) — based in Berkeley, CA and founded in 2005, develops and manufactures powered and artificially intelligent human exoskeletons for military, civilian and medical uses that augment strength, endurance, mobility and injury prevention.

Click here to see all recent news from this company

MIAMI BEACH, FL–(Marketwire – October 7, 2010) –  New You magazine, the premier consumer magazine for cosmetic surgery, announces the hiring of a new vice president of national sales, Amy Ammon.

Ms. Ammon will be responsible for directing sales to all pharmaceutical, cosmetic, and medical device companies nationwide.

Ms. Ammon brings to New You an extensive background in the aesthetic and dermatology markets. Prior to joining New You, she served as national account manager for Advanstar Communications (Dermatology Times and Cosmetic Surgery Times).

“I am confident that New You is the up-and-coming information resource for anything having to do with beauty, cosmetic surgery and anti-aging. It’s destined to become one of the top brands in our industry, reaching a highly motivated audience,” says Ms. Ammon.

New You is the official consumer magazine of the American Academy of Cosmetic Surgery, distributed to the waiting rooms of more than 2,000 cosmetic surgeons nationwide. It is also distributed to 1,500 bookstore newsstands and thousands of beauty businesses such as spas, medi-spas, health clubs, beauty salons and bridal shops.

The magazine is written for people interested in the latest and safest cosmetic procedures, from laser-assisted liposuction and breast augmentations to facial fillers and eyelifts, as well as how to find the best cosmetic surgeons nationwide.

“Amy brings an exceptional level of professionalism and understanding of the industry,” says New You Publisher Peter Mansfield. “She makes a great addition to the New You team.”

About New You Magazine

New You is the official magazine of the American Academy of Cosmetic Surgery (AACS), published by Miami Beach-based New You Publishing, LLC. The mission of New You is to inform readers about the latest cosmetic procedures, to educate them about safety, cost and personal experience, and to locate the best possible cosmetic surgeon. For more information visit: http://newyoumag.com

About The American Academy of Cosmetic Surgery

The American Academy of Cosmetic Surgery is a professional medical society dedicated to patient safety and physician education in cosmetic surgery. The AACS represents cosmetic surgeons in the American Medical Association through its seat in the AMA House of Delegates. Members of AACS are dermatological, facial plastic, head and neck, oral and maxillofacial, general, plastic, gynecological or ocular plastic surgeons specializing in cosmetic surgery. Founded in 1985, the AACS has over 2,500 members.

Click here to see all recent news from this company

ROCKINGHAM, NC–(Marketwire – October 7, 2010) –  Computer Zone, a leading provider of software and services for medical organizations, announced today that it is the first and only Value Added Reseller (VAR) able to sell and support certified complete EHR products for both physician practices and hospitals. Because of its extensive product line, Computer Zone can deliver an end-to-end solution that can help both hospitals and their associated practices comply with Meaningful Use requirements and work toward receiving funds under the ARRA stimulus program.

Under the ARRA stimulus program, separate certification programs have been established for hospitals and medical practices or “eligible providers.” In addition, EHR products can be certified as “Complete EHRs” that satisfy all certification criteria or can be certified as “EHR Modules” that meet some but not all of the criteria. 

To qualify for ARRA stimulus funds, both hospitals and providers must implement a certified complete EHR or a combination of appropriate certified EHR modules and comply with “Meaningful Use” guidelines. Hospitals and physicians practices that meet these requirements can receive substantial financial incentives.

Computer Zone delivers complete end-to-end solutions that meet all the ARRA requirements for both hospitals and medical practices. These solutions include:

• ChartAccess® EHR from Prognosis Health Information Systems for hospitals
• SuiteMed™ IMS from SuiteMed, LLC for the ambulatory environment
• Expert technical support, training and implementation services to support hospitals, doctors and staff members.

“Many organizations, hospitals and their associated physician practices are looking for one source to meet their EHR needs, both in-patient and ambulatory. At the same time, they want to make sure that they are using a certified EHR that will help them qualify for government financial incentives,” said Sandy Huggins, vice president of Computer Zone. “Computer Zone is the first and only VAR in the U.S. that can sell and support certified EHR software solutions for hospitals and their associated physician practices.”

About Computer Zone
Computer Zone is a comprehensive provider of technology solutions to medical organizations of all sizes and specialties from small medical offices to large clinics and mid-sized hospitals. Based in North Carolina and now serving medical organizations in all 50 states, Computer Zone delivers billing services, electronic medical records, practice management, electronic prescribing and ancillary medical applications and supports them with a range of services including custom development, training and on-going technical assistance. The company delivers these solutions using a proven and integrated implementation methodology and is dedicated to making medical organizations more successful. For more information, visit www.computerzone.net

UTICA, NY–(Marketwire – October 6, 2010) –  CONMED Corporation (NASDAQ: CNMD) announced today that it expects to report third quarter 2010 financial results before the market opens on Thursday, October 28, 2010, and will also hold a conference call live over the Internet at 10:00 a.m. Eastern Time that same day. This webcast can be accessed from CONMED’s web site at www.conmed.com. Replays of the call will be made available through November 5, 2010.

The Company anticipates that forward-looking information and additional material details related to third quarter 2010 earnings and the Company’s expectations on a prospective basis may be discussed during the call. Such forward-looking information may involve risks and uncertainties such as those described in the Company’s SEC filings.

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and monitoring. The Company’s products serve the clinical areas of sports medicine-arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. Surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology use our medical devices. Headquartered in Utica, New York, the Company’s 3,300 employees distribute its products worldwide from several manufacturing locations.

BURBANK, CA–(Marketwire – October 5, 2010) –  Imaging3™, Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, announced today that the company entered into a Securities Purchase Agreement with two institutional investors for the sale of common stock and warrants for $1 million.

The terms of the securities purchase agreement include the sale of 4,587,157 shares of common stock at 20% discount to Friday’s closing price ($0.218). The warrants include: (i) Series A Warrants, which are immediately exercisable for a period of 5 years into 4,587,157 shares at $0.2725 per share; (ii) Series B Warrants, which are immediately exercisable for a period of up to 18 months into 4,587,157 shares at $0.218 per share and (iii) Series C Warrants, which are immediately exercisable for a period of 5 years into 4,587,157 shares at $0.2725 per share but only to the extent that the Series B Warrants are exercised and only in the same percentage that the Series B Warrants are exercised. All of such warrants contain customary adjustments for corporate events such as reorganizations, splits, dividends, and the exercise prices of all such warrants are subject to full-ratchet anti-dilution adjustments in the event of additional issuances of common stock below the exercise price then in effect.

“This transaction will provide Imaging3 with sufficient working capital for the next year,” stated the company’s Chairman/CEO Dean Janes.

The completion of the offering is subject to the satisfaction of customary closing conditions and is expected to close on or before October 14, 2010. The net proceeds from this offering will be used solely for working capital purposes. In the securities purchase agreement, the company agreed not to use the proceeds to satisfy any debt, to redeem any of the company’s outstanding securities or with respect to any litigation involving the company.

The company will also provide customary resale registration rights in connection with the offering.

Wharton Capital Partners, Ltd., a New York based investment banking firm, acted as the placement agent for the company in this offering.

The shares of common stock and warrants being sold in the placement have not been registered under the Securities Act and may not be offered or sold without registration with the Securities and Exchange Commission, or under an applicable exemption.

About Imaging3

Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company’s website at http://www.imaging3.com for more information.

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, technological obsolescence, competition from other medical instrument(s) and imaging companies, lack of capital, unexpected costs, failure or delay of FDA approval, absence of revenue, the impact on the national and local economies resulting from an economic recession or terrorist actions, and U.S. actions subsequently; unavailability of financing for the Company or its customers, product malfunction and potential product liability claims, and other factors detailed in reports filed by the Company.

ALISO VIEJO, CA–(Marketwire – October 5, 2010) – Enclarity, Inc., a leading healthcare information solutions company, today announced the appointment of Warren Gouk as chief financial officer and head of business development. Gouk will oversee all of the company’s financial strategy, financial reporting, along with leading the company’s business and corporate development efforts. He joins Enclarity from Cascadia Capital, where he served as managing director and practice leader across various teams within the company’s investment banking practice.

“This has been a year of tremendous expansion for Enclarity, which included financial investments, strategic partnerships, significant new clients and industry recognition, and we foresee this growth accelerating,” said Sean Downs, chief executive officer, Enclarity. “By bringing Warren on board, we now have the expertise in place to help guide Enclarity into the next phase of development. His extensive experience building strategic relationships will help us both build and maintain partnerships with companies like Emdeon, along with expanding our focus into other healthcare and information service markets.”

At Cascadia Capital, Gouk built the firm’s physical security and Internet digital media teams into a top-three nationally ranked investment banking practice. He has spent his career advising private and public high-growth companies in the healthcare technology and data services markets. In addition, Gouk worked for five years with PricewaterhouseCoopers as a financial auditor to middle market companies across North America and as a strategic advisor to governments in Central America and the Caribbean pursuing privatizations and project finance transactions. Gouk holds a finance degree from the University of British Columbia, and has earned the Chartered Accountant (CA) and Chartered Financial Analyst (CFA) designations.

About Enclarity
Enclarity^® solves healthcare’s provider information problem. The company delivers correct, current and comprehensive provider information solutions by blending thousands of data sources, advanced analytics and healthcare expertise. As a result, its clients improve results in many areas, including claims processing, provider directories, regulatory compliance and market analysis. Named one of the Top 100 private technology companies in North America by Red Herring magazine and awarded the Global Healthcare Information Technology Excellence Award by Frost & Sullivan, Enclarity is headquartered in Aliso Viejo, Calif. For more information, visit www.enclarity.com.

Click here to see all recent news from this company

DALLAS, TX–(Marketwire – October 5, 2010) – The Biostatistics Center at Johns Hopkins University and the Department of Surgery at Duke University School of Medicine have selected FireHost, the leading secure, managed hosting provider, as their official Web host for special projects within their health care divisions. The websites and applications that FireHost will protect contain critical, confidential patient and research data that must remain secure.

Both Universities selected FireHost after conducting rigorous searches for a secure hosting provider that could achieve and maintain HIPAA (Health Insurance Portability and Accountability Act) requirements. Multiple layers of prevention protect every client within FireHost’s network, and the Web host is well versed in the additional precautions necessary to protect healthcare data for Duke and Johns Hopkins. Enterprise-grade Web hosting hardware including application level firewalls and DoS/DDoS mitigation devices are key components in providing a safe, HIPAA compliant-ready hosting environment for the Universities’ critical data.

“Medical organizations realize a high probability for cybercrime exists, and they must take every precaution possible to prevent a data breach. FireHost has built a reputation among healthcare organizations for protecting sensitive information online,” said Chris Drake, founder and CEO of FireHost. “We make it our priority to ward off vulnerabilities so Duke, Johns Hopkins, and all of our clients in healthcare can focus on what they do best, providing sophisticated research and patient care.”

Duke’s Center for Metabolic and Weight Loss Surgery has a Web application that stores patient data used to aid in the management and care throughout the program. James Alexander, systems analyst with the Duke Center for Metabolic and Weight Loss Surgery affirms, “There has never been a point in time in the field of healthcare service delivery that protection of patient information and privacy has been more important. Continually reviewing all of our systems and protections to make sure that we are well protected is yet another illustration of our primary commitment to our patients.”

The Biostatistics Center at the Johns Hopkins Bloomberg School of Public Health was looking for secure hosting for their Web-based data collection application. The application collects health research data that requires a high level of security and scalability, and FireHost was the clear choice. “We evaluated many providers and FireHost was our top choice to meet our secure hosting needs,” says Andre Hackman, faculty research associate of the Biostatistics Center. “Their support is the best we’ve ever worked with and the levels of security that they provide are unsurpassed. We have a great relationship with FireHost and I don’t hesitate to recommend FireHost to colleagues that are looking for secure hosting.”

FireHost has grown 150 percent in the first three quarters of 2010, and counts healthcare IT as one of its fastest growing segments along with Ecommerce and security companies. FireHost is an attractive, affordable alternative to traditional dedicated hosting. Medical SaaS providers and other professional services organizations that specialize in services that collect, store, and access protected patient information online have found the price, scalability, and protection they need with FireHost.

About FireHost, Inc.
FireHost, Inc. is a Dallas, Texas-based secure managed hosting company that delivers enterprise-quality hosting solutions. Specializing in protecting Web sites with compliance and high traffic needs, FireHost makes hacker prevention a standard part of every hosting plan. Advanced security combined with a comprehensive portfolio of hosting solutions helps FireHost protect companies of all sizes from threats to their Web sites, Web applications, and other valuable data.

Helpful links:
www.firehost.com
www.fireblog.com
Twitter.com/firehost

Click here to see all recent news from this company

ROYAL OAK, MI–(Marketwire – October 5, 2010) –  Bright Side Dental, a local Detroit dentist, has established the Bright Future Scholarship Program to assist deserving local high school students in obtaining a college education. Applicants must be a graduating senior with a 3.0 cumulative grade point average or higher and be involved in extracurricular activities. Qualified applicants will live within Bright Side Dental service areas of Sterling Heights, Royal Oak, Livonia, and Canton, Michigan.

“We understand the importance of education and giving back to the community, and we are proud to offer the Bright Future Scholarship to deserving students,” said Josh Gershonowicz, Vice President of Public Relations & Marketing for Bright Side Dental.

Each applicant is required to complete a one page essay in response to the topic: Explain the importance of maintaining good dental hygiene and how poor dental hygiene can affect your overall health.

Essays will be judged by a panel of dental health experts and two students will be selected to receive a $500 scholarship that can be used toward college expenses. Student’s essays must be submitted by April 15^th, 2011.

For more information and for how to apply, contact your local Bright Side Dental office or visit us online at http://www.brightsidedental.com/about-us/bright-future-scholarship/

About Bright Side Dental

Bright Side Dental is a member of the American Dental Association, Michigan Dental Association and Special Care Dentistry Association and offers a full array of dental, cosmetic and orthodontic services.

For more information about Bright Side Dental or to schedule an appointment, visit our website at www.BrightSideDental.com or call us at 1-800-PAINLESS.

Click here to see all recent news from this company

CHICAGO, IL–(Marketwire – October 4, 2010) –  Ziegler (PINKSHEETS: ZGCO), a specialty investment banking firm serving hospital and healthcare systems clients since 1928, announced the successful transaction closing for Bronson Methodist Hospital (Bronson). Bronson is a 405-licensed bed general acute care hospital located in Kalamazoo, Michigan; Bronson is a part of the Bronson Healthcare Group, Inc.

Ziegler has served as Bronson’s investment banker for over seven years. During the financial crisis of 2008, Ziegler worked diligently with Bronson to reduce the risk profile of its capital structure by removing counterparty risk to financial institutions and by reducing the risks associated with variable rate indebtedness. In early 2010, Ziegler presented the opportunity for Bronson to further reduce its balance sheet risk. The Series 2010 transaction included the conversion of the outstanding insured variable rate demand obligations to fixed-rate bonds totaling $75 million that carried Assured Guaranty insurance. By converting this series to fixed- rate bonds, Bronson was able to preserve the value of its bond insurance policy and minimize its capital costs. The second series, which totaled $114.26 million, was structured as unenhanced securities and carried an “A2” rating from Moody’s. In conjunction with the fixed-rate conversion, which reduced counterparty, basis, remarketing, and acceleration risks, Bronson terminated corresponding fixed-payer swaps to further reduce its balance sheet risk profile.

John Hanley, Ziegler’s newly promoted head of its healthcare practice, commented, “Bronson offers an excellent example of how Ziegler works with its clients to identify creative financing solutions that best meet their organization’s short- and long-term financial goals.”

For more information about Ziegler and this transaction, please visit us at www.Ziegler.com.

About Ziegler:
The Ziegler Companies, Inc. (PINKSHEETS: ZGCO) together with its affiliates (Ziegler) is a specialty investment bank with unique expertise in complex credit structures and advisory services. Nationally, Ziegler is ranked as one of the leading investment banking firms in its specialty sectors of healthcare, senior living, religion and education finance, as well as corporate finance and FHA/HUD. Headquartered in Chicago, IL with regional and branch offices throughout the U.S., Ziegler creates tailored financial solutions including bond financing, advisory, private placement, seed capital, M&A, risk and asset management. Ziegler serves institutional and individual investors through its wealth management and capital markets distribution channels.

Certain comments in this news release represent forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are subject to a number of risks and uncertainties, in particular, the overall financial health of the securities industry, the strength of the healthcare sector of the U.S. economy and the municipal securities marketplace, the ability of the Company to underwrite and distribute securities, the market value of mutual fund portfolios and separate account portfolios advised by the Company, the volume of sales by its retail brokers, the outcome of pending litigation, and the ability to attract and retain qualified employees.

TRAVERSE CITY, MI–(Marketwire – October 4, 2010) –  Versus Technology, Inc. (PINKSHEETS: VSTI) is pleased to announce that another phenomenal customer, Pacific Medical Center (PacMed), is now realizing the benefits of the Versus Advantages™ Real-time Locating System (RTLS). In April, Canyon Park Clinic, PacMed’s newest multi-specialty clinic in Bothell, WA, implemented the Versus Advantages™ Clinic solution to reduce patient visit times and improve the overall patient experience.

Taking time in September to share the Advantages of RTLS in Clinical Environments at Microsoft’s Health Users Group Exchange 2010, Brett Daniel, MD, Medical Director at Canyon Park Clinic announced that not only did the clinic achieve its primary goal to reduce overall average patient visit times from 70 to 46 minutes, it also reduced phone calls, demonstrated outstanding patient satisfaction scores, and is expected to promote material revenues. An impressive success, especially considering the RTLS was implemented only six months ago when the clinic opened.

“We were, and continue to be, focused on customer service, and the patient is our customer,” explains Linda Eremic, Director of Primary Care Services for PacMed. “Per our experience as both consumers and patients, we know that it makes sense to ensure that the customer is never left needlessly waiting–not in a waiting room, not in an exam room, not on the phone and not for a return call. Versus helps us manage our time and our patients to ensure that we can deliver the customer service our patients expect and deserve.” 

With up to 110 personnel on site and 300 patients currently moving in and about the Canyon Park Clinic‘s 30,000 sq. ft. each day, the Versus’ RTLS was sure to deliver benefit just in communicating the locations of patients, staff and equipment. However, for Versus, providing location information is just a necessary stepping stone to true clinical automation. PacMed is experiencing increased efficiencies as a result of:

1. Knowing patient status and room availability. (Communicated simultaneously to all care providers and updated automatically.)
2. No longer “rooming” patients. (Patients self-room, similar to checking in at a hotel.)
3. Reports to monitor Key Performance Indicators and measure results.
4. Alerts to ensure that providers and MAs see the patient at the right time, with the right information.

Dr. Daniel notes, “Every decision we made when designing the new clinic was centered on improving the patient experience. With Versus, what we didn’t expect is how great an impact it would also have on staff. Our staff is more productive, less stressed and patients have greater access to all of us. On the technology side, even our upcoming EMR implementation will be made easier by virtue of having the RTLS. As we anticipate greater distribution of the Versus system, our clinic has really become a model for how to do it well.”

“We really appreciate when our clients are willing to discuss the advantages of RTLS,” says HT Snowday, Versus’ CTO. “PacMed is unique in that they understood from the start that implementing RTLS wasn’t about simply tracking assets or choosing the technology that was easiest to install. It’s about delivering real, transformational change to patients and those who deliver patient care. To do so, facilities have to look beyond the locating technology to determine whether the solution offers clinical-quality data and whether the vendor understands the locating metrics as they relate to healthcare.”

Dr. Daniel will be presenting Canyon Park Clinic’s use case and outcomes with RTLS through an AHA Solutions, Inc. webinar on Wednesday, October 6, 2010. Those interested in learning more may register here: AHA Signature Learning Series – Patient Flow. 

About Pacific Medical Centers
Pacific Medical Centers is a private not-for-profit, multi-specialty health-care network of 10 locations with 140 primary and specialty care providers. Its 10 locations are in Puget Sound neighborhoods in Beacon Hill, Bothell, downtown Seattle, Northgate, Federal Way, First Hill, Lynnwood, Northgate, Renton and Totem Lake. Pacific Medical Centers serves patients with commercial insurance, retired military and their families, family members of active-duty personnel, as well as the underserved in our community.

About Versus Technology, Inc.
Established in 1988, Versus Technology, Inc. specializes in real-time location systems (RTLS) for healthcare. Used for enterprise patient tracking, bed management, asset tracking, and nurse call automation, Versus Advantages™ improves patient flow and documentation of caregiver and patient interactions, while enhancing communication and efficiency. Exclusively endorsed by the American Hospital Association, the Versus Advantages infrared (IR) and Active RFID solution is responsible for clinical-grade location and automation at a number of hospitals, clinics and long-term care facilities worldwide. To learn more about Versus Technology, Inc. (PINKSHEETS: VSTI), our technology and client successes, visit www.versustech.com and take the Advantages Tour.

Safe Harbor Provision
This release may include forward-looking statements which “bespeak caution,” and which are subject to risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. The statements are made only as of the date of this release, and the Company undertakes no obligation to update them to reflect subsequent events or circumstances.

Click here to see all recent news from this company

TAMPA, FL–(Marketwire – October 1, 2010) –  Zimek Technologies (www.zimek.com), a worldwide leader in infection control and biohazard remediation, today applauded the Center for Medicare and Medicaid Services (CMS) current efforts toward enhancing hospital quality standards, which among them include driving hospitals to meaningfully reduce healthcare-associated infections (HAIs).

“We support all regulatory efforts that push for a critical need to address HAIs, which according to the Centers for Disease Control (CDC) is a major concern with 3.5 million patients infected each year in hospitals and long-term care facilities due to HAIs,” said Kurt Grosman, CEO of Zimek Technologies. “As a business leader in the infection control industry, I intend to support the CMS by promoting meaningful infection control best practices which can reduce HAIs and save lives. Zimek’s state of the art infection control technology can clearly help hospitals all over the country meet the quality standards set forth by CMS to reduce overall Hospital-Acquired Conditions (HACs).” Last week, CMS suspended its plans to make HAC information available to the public due to a discrepancy which was identified between the claims data that hospitals submitted and the CMS data file that was used to calculate the HAC information.

Grosman pointed out that by utilizing Zimek Technologies, hospitals can save millions of dollars annually. “Preventing five of the most commonly occurring HACs could help a 200-bed facility save $2 million a year, which is documented by the Healthcare Management Council (HMC),” Grosman said. The savings relate to the extra services hospitals provide to treat related complications that arise. Infection due to medical care is one of the HACs that can result in nonpayment from Medicare, Medicaid, and in some cases private insurance.

In data provided by the Agency for Healthcare Research and Quality, HMC studied hospitals as small as 75 beds and as large as 800 beds to determine how much they spend on HAC-related patient care. The cost ranged from $8,300 per patient for care costs associated with accidental punctures to $24,500 per patient for care related to hospital-acquired infections.

Zimek’s industry-leading infection control technologies are used by the U.S. Department of Homeland Security, Department of Defense, fire and EMS departments, healthcare facilities, public health agencies, transit systems, correctional facilities, and local law enforcement agencies across America.

Zimek’s revolutionary Micro-Mist^® products “micronize” disinfectants that can quickly and automatically decontaminate facilities, equipment and vehicles. Zimek’s germ-killing Micro-Mist^® can permeate crevasses and hidden surfaces where super-germs are untouched by standard sanitizing methods.

“Zimek’s proven rapid infection control application is a meaningful 21^st century best practices infection prevention technology which will add another weapon to our arsenal to combat the spread of infectious diseases,” Grosman added.

FRANKFURT, GERMANY and LOS ANGELES, CA–(Marketwire – September 30, 2010) – PHIGroup, Inc., (OTCBB: PHIE) today announced that its subsidiary PHILand Ranch Ltd., a company engaged in the development of master-planned communities, residential and commercial properties, hospitality and healthcare services in Vietnam and Southeast Asia, (WKN A0RPEA) (FRANKFURT: 1P8) (XETRA: 1P8), has signed an agreement with Hanoi-based Huong Viet International Investment and Trade Joint Stock Company to co-develop the HH3 Project, part of the South An Khanh New City, about 10 kilometers (6.2 miles) from Central Hanoi, Vietnam.

The HH3 Project consists of 2.8 hectares (6.92 acres) along Lang Hoa Lac Highway in An Khanh Village, Hoai Duc District, Hanoi City, which has been approved for 40% mixed use construction, with seven 40-story building blocks to be built, 38 stories of which are allocated for residential purposes. PHILand Ranch will be responsible for engaging a renowned architectural firm to help design the project and jointly contributing capital towards the development and construction.

Total cost of the HH3 Project is estimated at $238.7 million while projected revenues range from $323.5 million to $582.2 million and net profits from $63.5 million to $257.7 million, based on a sale price of $1,000/square meter to $1,800/square meter. PHILand Ranch may own 50% to 70% of the project, based on actual resource contributions such as design work, capital contributed and project management.

According to Cushman Wakefield, the real estate market in Vietnam is showing signs of recovery in line with positive growth of the Vietnamese economy and Hanoi’s increasing population and urbanization ratio, which is predicted to be 30% in 2010 and 50% in 2020. Good investment returns are anticipated in all residential segments especially in the premium and executive levels since demand for houses for people with an average income always remains high.

Henry Fahman, Chairman of PHILand Ranch, said, “We are delighted to partner with Huong Viet, a group of real estate experts who possess in-depth knowledge of the local market, marketing savvy and a extensive client network, to develop the HH3 Project to meet the growing demand of the housing market in Hanoi and its surrounding areas. This is the first of our joint development projects with selective local Vietnamese partners as part of our growth strategy.”

About PHILand Ranch Ltd.
PHILand Ranch Limited, a United Kingdom corporation, is engaged in the development of master-planned communities, residential and commercial properties, hospitality and healthcare services in Vietnam and the growing economies of Southeast Asia. The company is currently developing the first phase of a multi-billion dollar project at Pointe91 in Bien Rang, Chu Lai, Quang Nam Province, Central Vietnam through its wholly owned Vietnam-based subsidiary PHILand Vietnam Ltd. PHILand Ranch’s stock is traded on the Frankfurt Stock Exchange (FRANKFURT: 1P8), (WKN A0RPEA). Website: www.PHILandranch.com.

About PHIGroup, Inc.
PHIGroup (OTCBB: PHIE) provides M&A advisory and consulting services, develops real estate and natural resources and invests in special situations. PHIGroup, which specializes in raising capital and helping take companies public, is developing PHILand Ranch, one of the largest master planned communities in Vietnam. This project includes Pointe91, a luxury resort and premium residential community in Quang Nam province in central Vietnam (www.PHILandranch.com). PHIGroup is also engaged in mining activities through its majority-owned subsidiary PHI Mining Group, Inc. (www.phimining.com). Website: www.phiglobal.com.